Cheap semaglutide in 2026 comes from four main legitimate paths: compounded semaglutide via telehealth ($199 to $349 per month), commercial insurance plus the Ozempic or Wegovy Savings Card ($25 per month copay for qualifying patients), Medicare Part D for type 2 diabetes coverage, and Novo Nordisk patient assistance for low-income uninsured patients. Compounded semaglutide remains legal while the FDA drug shortage continues but could end within months if the shortage resolves. Overseas and “research only” products are illegal and dangerous.
Legitimate Cheap Semaglutide Options Compared
| Path | Monthly Cost | Requires | Notes |
|---|---|---|---|
| Compounded semaglutide via telehealth | $199–$349 | Telehealth consultation | Legal while shortage continues; ends when shortage resolves |
| Commercial insurance + Ozempic Savings Card | $25 | T2D diagnosis, PA approval | Annual savings cap applies |
| Commercial insurance + Wegovy Savings Card | $25–$550 (3-mo) | Weight-loss eligibility, PA approval | Plan coverage varies widely |
| Medicare Part D (Ozempic for diabetes) | Standard Part D copay ($10–$100) | T2D diagnosis | 2024 IRA caps apply |
| Medicare Part D (Wegovy for CV risk) | Varies | Established CV disease, BMI criteria | New indication added 2024 |
| Novo Nordisk patient assistance | Free or low cost | Low income, uninsured or under-insured | Income typically below 400% of federal poverty |
| GoodRx retail discount | $800–$1,000 | Prescription | Less savings than card or telehealth |
| Retail cash (no program) | $950–$1,400 | Prescription | Standard price without discounts |
Option 1: Compounded Semaglutide via Telehealth
Common Telehealth Platforms
- Hims / Hers: $199 oral or $299–$349 injectable per month
- Henry Meds: $297–$349 flat monthly
- Mochi Health: $79 membership + $99–$250 medication
- Ro Body: $99 first month, $99–$199 ongoing
- Found: $99–$299 per month
- Noom Med: $149–$299 per month
- Eden: $146–$296 per month
- MochiMD, Willow, HHVB: similar ranges, varying bundles
What’s Included
- Intake questionnaire and clinician consultation (async or video)
- Prescription for compounded semaglutide
- Dispensing by partner 503A pharmacy
- Cold-chain monthly shipping
- Ongoing clinician messaging and titration support
Shortage Status Risk
Compounded semaglutide is legal only while branded semaglutide remains on the FDA shortage list. Novo Nordisk has been scaling manufacturing and the shortage could resolve at any time. When it does:
- 503A pharmacies would be required to stop general compounding
- 503B outsourcing facilities similarly
- Narrow clinical-need exceptions would remain but not be broadly accessible
- Patients would need to transition to branded Ozempic or Wegovy (or switch to tirzepatide, which is already out of shortage)
Option 2: Commercial Insurance + Savings Card
Ozempic Savings Card (Type 2 Diabetes)
- Commercial insurance copay reduced to as low as $25 per month
- Annual savings cap applies (typically up to $1,850 per year)
- Not valid for Medicare, Medicaid, TRICARE, or other government plans
- Register at the Ozempic Savings Card website
- Prior authorization almost always required for insurance coverage
Wegovy Savings Card (Weight Loss)
- Commercial insurance copay reductions vary widely
- Typical range: $25 per month (limited) to $550 per 3-month supply
- Annual savings cap applies
- Not valid for government insurance
- Insurance coverage for weight loss alone is plan-dependent; many plans deny
Prior Authorization Success Tips
- Document BMI, weight-related comorbidities (hypertension, dyslipidemia, T2D, OSA)
- List prior weight-loss attempts (some plans require a 6-month supervised program)
- Your clinician’s office usually handles the PA; ask them to appeal denials
- Many first-pass denials succeed on appeal with better documentation
Option 3: Medicare Part D
Ozempic for Type 2 Diabetes
- Covered by most Medicare Part D plans
- Subject to standard Part D tier cost-sharing
- 2024 Inflation Reduction Act $2,000 annual out-of-pocket cap applies
- Typical monthly copay $10 to $100 depending on plan
Wegovy for Cardiovascular Risk Reduction
- FDA approved Wegovy for cardiovascular risk reduction in March 2024
- Some Part D plans now cover Wegovy for patients with established CV disease and BMI ≥ 27
- Check your specific plan’s formulary
- Medicare does not cover Wegovy for weight loss alone
Option 4: Novo Nordisk Patient Assistance
- Free or low-cost Ozempic for qualifying US patients
- Income typically must be below 400 percent of federal poverty level
- Uninsured or insurance denies coverage
- Apply at novonordisk.com patient programs
- Wegovy may also be available through patient assistance for some eligible patients
- Typically requires renewal annually
Red Flags to Avoid
- Price under $150 per month without consultation or prescription
- Ships from India, China, Mexico, or eastern Europe
- Labeled “research use only” — not for human use
- Advertised as “semaglutide sodium” or “semaglutide acetate” — FDA has stated these salt forms are not the same drug and should not be compounded
- No prescription or clinician consultation required
- Crypto-only or wire-transfer payment
- Social media DM sales (Instagram, Facebook, WhatsApp)
- No named US state pharmacy license
- No pharmacist-in-charge listed
- No physical US address on the website
Decision Flow
- Have commercial insurance? → Ask clinician to submit for Ozempic or Wegovy with Savings Card → often $25/month
- Have Medicare and T2D? → Part D covers Ozempic at standard Part D copay
- Have Medicare and established CV disease plus BMI? → Part D may cover Wegovy for CV risk reduction
- No insurance, want weight loss? → Compounded semaglutide via telehealth ($199–$349/month)
- Low income, uninsured? → Apply to Novo Nordisk patient assistance
- No insurance, need T2D treatment urgently? → Retail with GoodRx ($800–$1,000) then apply for patient assistance
Planning for Shortage Resolution
Compounded semaglutide will likely end in 2026 or 2027 as Novo Nordisk manufacturing scales. Plan ahead:
- Track FDA shortage status quarterly
- Discuss transition plan with your prescribing clinician
- Identify insurance pathway for branded Ozempic or Wegovy
- Consider trying branded tirzepatide (Mounjaro or Zepbound) as an alternative
- If compounded semaglutide is discontinued suddenly, weight regain typically begins within 4 to 6 weeks
Related Reading
See our guides on treatment options, reversibility, and our specific guide on choosing a compounding pharmacy.
The Bottom Line
Cheap semaglutide in 2026 comes from compounded telehealth ($199–$349 per month, legal while shortage continues), commercial insurance plus the Savings Card ($25 per month copay for qualifying patients), Medicare Part D for type 2 diabetes coverage at standard cost-sharing, and Novo Nordisk patient assistance for low-income uninsured patients. Avoid overseas, “research only,” and no-prescription sellers — these are illegal and often dangerous. Plan for the eventual end of the semaglutide shortage by identifying a path to branded Ozempic or Wegovy before your supply disappears.
